Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank100
3Y CAGR+28.4%
5Y CAGR+17.1%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+28.4%/yr
vs +8.7%/yr prior
5Y CAGR
+17.1%/yr
Recent acceleration
Acceleration
+19.7pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
3 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 1.94 | +32.8% |
| 2024 | 1.46 | +40.7% |
| 2023 | 1.04 | +13.4% |
| 2022 | 0.92 | -30.1% |
| 2021 | 1.31 | +48.5% |
| 2020 | 0.88 | -8.6% |
| 2019 | 0.97 | +47.2% |
| 2018 | 0.66 | -36.3% |
| 2017 | 1.03 | -5.2% |
| 2016 | 1.09 | - |